Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

917.97 +0.85 (+0.09%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,286,916
Open 917.18
Bid (Size) 907.68 (1)
Ask (Size) 917.90 (1)
Prev. Close 917.12
Today's Range 905.62 - 920.92
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million
These hot growth stocks may not be running out of steam just yet. 
Via The Motley Fool
AskSlim Market Week - Friday, Oct. 19
An analysis and commentary on the financial markets. 
Via Talk Markets

Performance

YTD
+55.01%
+55.01%
1 Month
+1.44%
+1.44%
3 Month
+7.06%
+7.06%
6 Month
+26.39%
+26.39%
1 Year
+55.38%
+55.38%

More News

Read More
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Exploring NYSE:LLY's high growth characteristics.
Via Chartmill
Eli Lilly Unusual Options Activity
Via Benzinga
2 High-Flying Growth Stocks With Massive Upside Potential
Via The Motley Fool
This is Huge News For Eli Lilly Investors
Via The Motley Fool
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Via Investor's Business Daily
Exposures Product Safety
This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Via The Motley Fool
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Via The Motley Fool
Exposures Product Safety
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Via Talk Markets
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Via Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
Via Benzinga
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
Via Benzinga
Topics Stocks
Exposures US Equities
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Via The Motley Fool
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.